Apimeds Pharmaceuticals US, Inc.
Ticker: 1894525
P/L Snapshot
Q3 FY26 · consolidated
vs Q2 FY26
Revenue
2.90
+935.7%
Expenditure
0.87
-95.7%
Net Profit
33.65
+266.8%
OPM %
70.03%
Shareholding
Pattern breakdown
P/L Trends
(in millions)
RevenueExpenditureNet Profit
Price Chart
Latest News
Corporate Events
Board MeetingAPUS
202629Sep
Board Meeting
Erick Frim resigned as Interim Chief Financial Officer and E…
SEC Filing ↗ Board MeetingAPUS
202610Sep
Board Meeting
The Board composition has been restructured following an ame…
SEC Filing ↗ Board MeetingAPUS
20265Aug
Board Meeting
Appointment of Dr. Christopher Kim as Chief Scientific Offic…
SEC Filing ↗ Board MeetingAPUS
20264May
Board Meeting
Appointment of Sungjoon Chae as Co-Chief Executive Officer …
SEC Filing ↗ Board MeetingAPUS
202624Apr
Board Meeting
Apimeds Pharmaceuticals US, Inc. entered into a Confidential…
SEC Filing ↗ Board MeetingAPUS
202620Mar
Board Meeting
Clarification that previously reported purported removals of…
SEC Filing ↗